'HAE' now, don't dream: Kalvista game hardly over, bid enters crowded house July 18, 2019 By Randy Osborne Kalvista Pharmaceuticals Inc. made big news in October 2017 by way of its handsome deal with Merck & Co. Inc. to advance KVD-001, an intravitreal injection candidate to treat diabetic macular edema (DME).Read More
